|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Aceto Corporation Announces Rising Pharmaceuticals, Inc Subsidiary Launches Generic Version of Ancobon(R) Capsules and Aralen(R) Tablets
11/21/2011 1:03:03 PM
PORT WASHINGTON, N.Y., Nov. 21, 2011 (GLOBE NEWSWIRE) -- Aceto Corporation (Nasdaq:ACET - News), a global leader in the marketing and distribution of pharmaceutical intermediates and active ingredients, finished dosage form generics, nutraceuticals products, agricultural protection products and specialty chemicals today announced that Rising Pharmaceuticals Inc., its generic finished dosage form subsidiary, has launched the 250 mg and 500 mg strengths of Flucytosine(R) Capsules, the first approved generic version of Valeant Pharmaceuticals International's Ancobon(R) Capsules, and 500 mg strength of Chloroquine Phosphate(R) Tablets, an approved generic version of Sanofi Aventis US's Aralen(R) Tablets, following the U.S. Food and Drug Administration (FDA) approval of both Abbreviated New Drug Applications (ANDA's). According to IMS Health data, U.S. brand sales for Flucytosine(R), which is used in the treatment of serious infections, and Chloroquine Phosphate(R), which is used to treat and prevent malaria infections, were approximately $20 Million collectively for the twelve months ended June, 2011.
|
|
|
|
|
|
|
|
|
|
|